Singapore-Based $4 Billion Asia Healthcare Private Equity Firm Quadria Capital Raised $1 Billion for Fund III ($954 Million Primary & $114 Million Co-Investment) & with Additional $300 Million Co-Investment Capacity, $600 Million Fund II Launched in 2020, Largest Existing Investors Include North America & Europe Sovereign Wealth Funds, Asset Managers & Strategic Corporates, New Investors from Saudi Arabia, UAE, Bahrain & India
28th May 2025 | Hong Kong
Singapore-based Asia healthcare private equity firm Quadria Capital ($4 billion AUM) has raised $1 billion for Fund III ($954 million Primary & $114 million Co-Investment), and with additional $300 million co-investment capacity. Quadria Capital $600 million Fund II was launched in 2020. Quadria Capital largest existing investors include North America & Europe sovereign wealth funds, asset managers & strategic corporates. For $1 billion Fund III, Quadria Capital has also raised funds from new investors in Saudi Arabia, UAE, Bahrain & India. Announcement (25/5/25): “Quadria Capital Asia’s premier healthcare-focused private equity firm, today announced the final close of its Fund III with US$1.07 billion in total commitments, significantly exceeding its original $800 million target. The oversubscribed fundraise comprises over US$954 million in primary commitments and US$114 million in committed co-investment capital. An additional US$300 million co-investment capacity is anticipated over the course of the investment phase, bringing total committed capital to approximately US$1.3 billion upon full deployment. This latest fundraise is around 60% larger than the firm’s previous $600m fund raised in 2020, cementing Quadria’s position as the largest dedicated healthcare private equity fund in South and Southeast Asia … … At a time when global capital is cautious, Quadria’s ability to consistently attract top-tier global investors underscores the strong conviction in its investment strategy and the undeniable opportunities in the Asian healthcare market. Quadria Capital’s largest existing backers include prominent North American and European sovereign wealth funds, asset managers, and strategic corporates. The Fund also secured new commitments from globally recognized institutional investors. Most notably, there was strong backing from leading institutions across the GCC, including Saudi Arabia, the UAE, and Bahrain. The fundraise further attracted interest from India, with fresh capital from major banks, insurance companies, and family offices. Additionally, the Fund received robust re-up commitments from impact investors – underscoring Quadria’s continued dedication to scalable, high-impact healthcare businesses that deliver lifesaving care to underserved populations across Asia. Fund III will build a diversified portfolio of approximately 10 market-leading companies, taking both significant minority and majority stakes, and further scaling impact through targeted co-investments from Limited Partners (LPs). Already nearly 40% deployed – including closed and signed investments – the fund has invested in Aragen Life Sciences (a global CRDMO serving over 400 pharma clients), NephroPlus (Asia’s largest dialysis chain), and Maxivision (India’s leading eye care chain). Two new investments in Southeast Asia are expected soon. Fund III builds on Quadria Capital’s track record of successful exits from Funds I and II, underscoring the strength of its investment strategy, operational expertise and ability to distribute capital back to investors.”
” Singapore-Based $4 Billion Asia Healthcare Private Equity Firm Quadria Capital Raised $1 Billion for Fund III ($954 Million Primary & $114 Million Co-Investment) & with Additional $300 Million Co-Investment Capacity, $600 Million Fund II Launched in 2020, Largest Existing Investors Include North America & Europe Sovereign Wealth Funds, Asset Managers & Strategic Corporates, New Investors from Saudi Arabia, UAE, Bahrain & India “
![](https://www.caproasia.com/wp-content/uploads/2025/08/Air-Charter-Service-728x90-1.png")
Abrar Mir, Co-Founder & Managing Partner, Quadria Capital: “Fund III’s close, amid one of the most demanding fundraising climates in recent memory, is a powerful validation of our strategy and our mission. It reflects deep global investor conviction in the transformational opportunity in Asian Healthcare, where social impact and financial performance go hand in hand … … With Asia expected to drive 40% of global healthcare growth by 20301, Fund III positions Quadria to lead a new era of private capital-driven healthcare transformation across the region.”
Dr Amit Varma, Co-Founder and Managing Partner, Quadria Capital: “Asia’s healthcare sector is at a pivotal moment, and it will remain in the limelight in 2025, especially with investment interest in India in areas like single-specialty hospitals, diagnostic chains, medical devices, and pharmaceutical manufacturing, which includes APIs and CDMOs. This sector will see growth because of higher healthcare consumption, cost-efficiency initiatives, and deepening technology integration. We are entering a golden decade of healthcare transformation”
Quadria – Founded in 2012, Quadria Capital is Asia’s premier healthcare investor managing over US$4 billion in assets across 27 investments in South and Southeast Asia including India, Vietnam, Indonesia, Malaysia and Singapore. Quadria Capital aims to create significant and sustainable shareholder value by partnering with exceptional healthcare businesses to enhance their impact and scale, while generating superior returns for investors.
Singapore-Based $4 Billion Asia Healthcare Private Equity Firm Quadria Capital Raised $1 Billion for Fund III ($954 Million Primary & $114 Million Co-Investment) & with Additional $300 Million Co-Investment Capacity, $600 Million Fund II Launched in 2020, Largest Existing Investors Include North America & Europe Sovereign Wealth Funds, Asset Managers & Strategic Corporates, New Investors from Saudi Arabia, UAE, Bahrain & India
Caproasia Users
- Manage $20 million to $30 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2026 Investment Day
- March - Hong Kong
- March - Singapore
- April - Hong Kong
- April - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
